Abstract
Worldwide, the treatment of tuberculosis is based on evidence-based guidelines developed by the World Health Organization (WHO) for national tuberculosis programs. However, the importance of health related quality of life, the adequate management of side effects associated with antituberculosis drugs and the elaboration of tuberculosis treatment outcome categories are a few issues that need to be addressed in forthcoming WHO guidelines for the treatment of tuberculosis.
Similar content being viewed by others
References
World Health Organization. Treatment of Tuberculosis Guidelines; 2009. Report No.: WHO/HTM/TB/2009/420. ISBN: 9789241547833.
World Health Organization. Preamble to the constitution of the World Health Organization as adopted by the International Health Conference. International Health Conference; New York. 1946 [cited 1 May 2012]; Available from: http://whqlibdoc.who.int/hist/official_records/constitution.pdf.
Spilker B. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven Philadelphia; 1996. ISBN: 0781703328.
Rajeswari R, Muniyandi M, Balasubramanian R, Narayanan PR. Perceptions of tuberculosis patients about their physical, mental and social well-being: a field report from south India. Soc Sci Med. 2005;60(8):1845–53.
Sherbourne CD, Sturm R, Wells KB. What outcomes matter to patients? J Gen Intern Med. 1999;14(6):357–63.
Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes. 2004;2(1):58.
Hansel NN, Wu AW, Chang B, Diette GB. Quality of life in tuberculosis: patient and provider perspectives. Qual Life Res. 2004;13(3):639–52.
Macq J, Solis A, Martinez G, Martiny P, Dujardin B. An exploration of the social stigma of tuberculosis in five. Health Policy. 2005;74(2):205–17.
Guo N, Marra F, Marra CA. Measuring health-related quality of life in tuberculosis: a systematic. Health Qual Life Outcomes. 2009;7:14.
Dhuria M, Sharma N, Ingle GK. Impact of tuberculosis on the quality of life. Indian J Commun Med. 2008;33(1):58–9.
Dhingra VK, Rajpal S. Health related quality of life (HRQL) scoring (DR-12 score) in tuberculosis–additional evaluative tool under DOTS. J Commun Dis. 2005;37(4):261–8.
Li LM, Bai LQ, Yang HL, Xiao CF, Tang RY, Chen YF, et al. Sputum induction to improve the diagnostic yield in patients with suspected pulmonary tuberculosis notes from the field. Int J Tuberc Lung Dis. 1999;3(12):1137–9.
Parry CM, Kamoto O, Harries AD, Wirima JJ, Nyirenda CM, Nyangulu DS, et al. The use of sputum induction for establishing a diagnosis in patients with suspected pulmonary tuberculosis in Malawi. Tuber Lung Dis. 1995;6(1):72–6.
Leigh TR, Hume C, Gazzard B, Parsons P, Husain OAN, Collins JV. Sputum induction for diagnosis of Pneumocystis carinii pneumonia. Lancet. 1989;334(8656):205–6.
Shata AM, Coulter JB, Parry CM, Ching’ani G, Broadhead RL, Hart CA. Sputum induction for the diagnosis of tuberculosis. Arch Dis Child. 1996;74(6):535–7.
Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest. 1997;99(1):9–13.
Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed). 1981;283(6302):1285–7.
Gonzalez-Angulo Y, Wiysonge CS, Geldenhuys H, Hanekom W, Mahomed H, Hussey G, Hatherill M. Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2011 [Epub ahead of print]. Available from: http://www.springerlink.com/content/er6674p5785711rg/.
Crofton J, Horne NW, Miller F. Clinical tuberculosis. London: The Macmillan Education Limited; 2008. ISBN: 140509737X.
Atif M, Sulaiman SAS, Shafie AA, Muttalif AR, Ali I, Saleem F. Applying patient centered approach in management of pulmonary tuberculosis: a case report from Malaysia. J Basic Clin Pharm. 2011;2(3):129–31.
Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(S3):163–70.
Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clinical Pharmacol. 1999;55(2):85–93.
Woodward JK. Pharmacology of antihistamines. J Allergy Clin Immunol. 1990;86(4):606–12.
Funding
Authors would like to thank Institute of Postgraduate Studies (IPS) at University Sains Malaysia for their financial support in carrying out this work through USM-RU-PRGS (1001/PFARMASI/844011).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Atif, M., Sulaiman, S.A.S., Shafie, A.A. et al. WHO guidelines for treatment of tuberculosis: the missing links. Int J Clin Pharm 34, 506–509 (2012). https://doi.org/10.1007/s11096-012-9657-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-012-9657-8